Video

Dr. Tap on Olaratumab in Patients With Soft Tissue Sarcoma

Author(s):

William D. Tap, MD

In Partnership With:

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumab as a treatment for patients with soft tissue sarcoma.

Olaratumab is unique because it is a monoclonal antibody that specifically targets the platelet-derived growth factor receptor (PDGFR). Although it was thought that this therapy would require a cellular signaling process, researchers initially believed that the entire PDGFR cellular signaling had to be repressed.

However, olaratumab is highly specific to PDGFR-α. Because olaratumab is associated with a significant improvement in overall survival, researchers are beginning to rethink how it affects immune cells, stem cells, and the tumor microenvironment. Tap hopes that olaratumab will help researchers understand more of the biology of sarcoma.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Related Content
James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
November 12th 2024

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27